VP, Head of Bioanalytical & CMC Analytical Development at Sigilon Therapeutics
Jiang Wu, Ph.D., has over 20 years of industry experience in implementing bioanalytical/biomarker strategy, managing preclinical and clinical trials, and developing biologics. Prior to joining Sigilon, Dr. Wu worked at Takeda as a director of preclinical and translational sciences. He was responsible for bioanalytical, biomarker and in vitro diagnostic strategy and assay implementation to support early and late stage programs across multiple therapeutic areas. Previously, Dr. Wu served as an Associate Research Fellow and Lab Head at Pfizer/Wyeth where his team utilized a variety of techniques to identify novel targets and biomarkers and elucidate drug MOAs in support of drug discovery and translational medicine. Before joining Wyeth, he was a biomarker group lead at Millennium Pharma and a senior scientist at Abbott Lab.
VP, Head of Bioanalytical & CMC Analytical Development